Who owns AN2 THERAPEUTICS INC?
- Ticker: ANTX
- CUSIP Number: 037326105
Tip: Access positions for across all investors
Analyze quarterly positions in An2 Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of An2 Therapeutics stock
Who bought or sold AN2 THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 5.6M | $114M | 0% | Dec 2023 |
|
| BVF | 1.6M | $32M | 0% | Dec 2023 |
|
| Citadel Advisors | 1.6M | $32M | 0% | Dec 2023 |
|
| Frazier Life Sciences Management | 1.4M | $29M | 0% | Dec 2023 |
|
| Henderson Group | 1.3M | $26M | -8% | Dec 2023 |
|
| Avidity Partners Management | 1.1M | $23M | 5% | Dec 2023 |
|
| Vanguard Group | 1.1M | $22M | 12% | Dec 2023 |
|
| Octagon Capital Advisors | 665k | $14M | -23% | Dec 2023 |
|
| Marshall Wace | 337k | $6.9M | -53% | Dec 2023 |
|
| Nantahala Capital Management | 248k | $5.1M | -30% | Dec 2023 |
|
| T. Rowe Price Associates | 187k | $3.8M | 100% | Dec 2023 |
|
| Citigroup | 161k | $3.3M | 1% | Dec 2023 |
|
| Jane Street | 59k | $1.2M | 100% | Dec 2023 |
|
| Victory Capital Management | 52k | $1.1M | -1% | Dec 2023 |
|
| Alyeska Investment Group | 50k | $1.0M | 0% | Dec 2023 |
|
| RMB Capital Management | 46k | $941k | 0% | Dec 2023 |
|
| Barclays | 44k | $907k | 1296% | Dec 2023 |
|
| Laurion Capital Management | 44k | $898k | 100% | Dec 2023 |
|
| Millennium Management | 40k | $813k | 100% | Dec 2023 |
|
| Deutsche Bank Aktiengesellschaft | 40k | $809k | 100% | Dec 2023 |
|
| Monashee Investment Management | 34k | $697k | -66% | Dec 2023 |
|
| Captrust Financial Advisors | 29k | $587k | 0% | Dec 2023 |
|
| TD Asset Management | 26k | $529k | 100% | Dec 2023 |
|
| Chicago Partners Investment | 22k | $52k | 100% | Mar 2024 |
|
| Bank of America Corporation | 22k | $449k | 607% | Dec 2023 |
|
| Balyasny Asset Management | 19k | $395k | 100% | Dec 2023 |
|
| Two Sigma Investments | 19k | $394k | 100% | Dec 2023 |
|
| Man Group | 18k | $376k | 100% | Dec 2023 |
|
| Cubist Systematic Strategies | 17k | $338k | 100% | Dec 2023 |
|
| Goldman Sachs Group | 14k | $288k | 100% | Dec 2023 |
|
| 683 Capital Management | 13k | $274k | 100% | Dec 2023 |
|
| Point72 Asia | 621.00 | $13k | 100% | Dec 2023 |
|
| Advisor Group Holdings | 300.00 | $6.1k | 50% | Dec 2023 |
|
| Federated Investors | 258.00 | $5.3k | 163% | Dec 2023 |
|
| Rhumbline Advisers | 250.00 | $5.1k | 0% | Dec 2023 |
|
| Wells Fargo & Company | 126.00 | $2.6k | 103% | Dec 2023 |
|
Who sold out of An2 Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| UBS Group | Sep 2023 | 41k | $660k |
| Heritage Wealth Advisors | Sep 2023 | 1.1k | $17k |